PT - JOURNAL ARTICLE AU - Yang, Xinzhuang AU - Zhang, Dingding AU - Li, Pidong AU - Niu, Jingwen AU - Xu, Dan AU - Guo, Xueyu AU - Wang, Zhen AU - Zhao, Yanhuan AU - Ren, Haitao AU - Ling, Chao AU - Wang, Yang AU - Shen, Jianxiong AU - Zhu, Yicheng AU - Wang, Depeng AU - Cui, Liying AU - Chen, Lin AU - Dai, Yi TI - Expansion of 5’ UTR CGG repeat in RILPL1 is associated with oculopharyngodistal myopathy AID - 10.1101/2021.09.18.21263669 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.18.21263669 4099 - http://medrxiv.org/content/early/2021/09/29/2021.09.18.21263669.short 4100 - http://medrxiv.org/content/early/2021/09/29/2021.09.18.21263669.full AB - Oculopharyngodistal myopathy is an adult-onset degenerative muscle disorder characterized by ptosis, ophthalmoplegia and weakness of the facial, pharyngeal and limb muscles. Trinucleotide repeat expansions in non-coding regions of LRP12, G1PC1and NOTCH2NLC were recently reported to be the etiologies for OPDM. However, a significant portion of OPDM patients still have unknown genetic causes. In this study, we performed long-read whole-genome sequencing in a large five-generation family of 156 individuals, including 22 patients diagnosed with typical OPDM and identified CGG repeat expansions in RILPL1 gene in all patients we tested while not in unaffected family members. Methylation analysis indicated that methylation levels of the RILPL1 gene were unaltered in OPDM patients, which was in consistent with previous reports. Our findings first provided evidences that RILPL1 were associated OPDM which we suggested as OPDM type 4.Competing Interest StatementThe authors have declared no competing interest.Funding Statementthe present study was funded by the CAMS Innovation Fund for Medical Sciences (CIFMS), the Project number 2016-I2M-1-002, and the National Key Research and Development Program of China, Grant no. 2016YFC0901502. and the National Natural Science Foundation of China [31900481]. we declared that none of the authors or their institutions at any time received payment or services from a third party for any aspect of the submitted work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The present study has been approved by the Ethics Committees of Peking Union Medical College Hospital. And the written informed consent forms were obtained from all the study participant. Furtherly, we have shared the study findings with all the study participants.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yeswe, all the authors, have the availability of all data used in the present manuscript.